Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masashi Kanemoto is active.

Publication


Featured researches published by Masashi Kanemoto.


Journal of Cardiovascular Electrophysiology | 2003

New Method of Determining the Atrial Fibrillation Cycle Length During Human Atrial Fibrillation

Akihiko Shimizu; Yasuhiro Yoshiga; Toshihiko Yamagata; Masahiro Esato; Masahiro Doi; Hiroyuki Kakugawa; Ryousuke Kametani; Noriko Inoue; Masashi Kanemoto; Masunori Matsuzaki

Introduction: The aim of this study was to investigate the usefulness of the autocorrelation function (reversed fast Fourier transform analysis) in determining the atrial fibrillation cycle length (AFCL) during human atrial fibrillation (AF).


Case reports in cardiology | 2015

A Rare Case of Complete Stent Fracture, Coronary Arterial Transection, and Pseudoaneurysm Formation Induced by Repeated Stenting

Fumiaki Nakao; Masashi Kanemoto; Jutaro Yamada; Kazuhiro Suzuki; Hidetoshi Tsuboi; Takashi Fujii

This report describes a rare asymptomatic case of complete stent fracture, coronary arterial transection, and pseudoaneurysm formation in response to repeated stenting. The proximal and distal ends of transected coronary artery were closed, and distal bypass was performed. Coronary arterial transection can occur in patients with repeated stenting as a long-term adverse event.


Journal of Cardiology | 2013

Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P

Motoki Fukutomi; Nobuaki Tanaka; Hitoshi Uchinoumi; Masashi Kanemoto; Fumiaki Nakao; Jutaro Yamada; Toshiaki Kamei; Toshihiro Takenaka; Takashi Fujii

BACKGROUND Fabry disease, an X-linked lysosomal sphingolipid storage disorder caused by mutation of the α-galactosidase A (GLA) gene, results in systemic organ damage. However, the age of onset of clinical manifestations and course of the disease are variable even within the same family. OBJECTIVE In this study, we evaluated the clinical phenotype and the molecular lesions associated with the GLA gene in a Japanese family with Fabry disease that predominantly showed cardiac and neurological manifestations. METHODS A genetic analysis of the GLA gene using conventional genomic sequencing was performed in all seven members of this family, including four hemizygous males and three heterozygous females. Endomyocardial biopsy was performed in two patients with severe left ventricular (LV) hypertrophy. RESULTS A novel missense mutation was identified at codon 220 in exon 5, thus resulting in an arginine to proline substitution (R220P) in all seven family members. The three adult hemizygous males had LV hypertrophy and developed neurological manifestations in their 50s. One of the adult hemizygotes developed complete atrioventricular block. On the other hand, we could not find any organ damage in a young hemizygous male or the three heterozygous females. CONCLUSION We identified a novel missense mutation in a Japanese family with Fabry disease showing cardiac and neurological manifestations. In patients with Fabry disease, advanced organ damage in the heart and brain can be life-threatening, even if renal failure is lacking.


Cardiovascular Drugs and Therapy | 2004

Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.

Masashi Kanemoto; Akihiko Shimizu; Toshihiko Yamagata; Masahiro Esato; Takeshi Ueyama; Yasuhiro Yoshiga; Hiroyuki Kakugawa; Ryousuke Kametani; Noriko Inoue; Akira Sawa; Masunori Matsuzaki

AbstractThe purpose of this study was to identify the difference between the pure Na channel blocker, pilsicainide and Ic-antiarrhythmic drug, flecainide, on the atrial electrophysiological characteristics. Methods: The subjects consisted of 24 patients (48 ± 12 years-old: P-group) in whom pilsicainide was administrated intravenously (1 mg/kg/10 min) and 31 patients (47 ± 15 years-old: F-group) in whom flecainide was administrated intravenously (2 mg/kg/10 min). The atrial effective refractory period (ERP-A), intra-atrial conduction time (CT), max intra-atrial conduction delay (Max CD), repetitive atrial firing zone (RAFZ), fragmented atrial activity zone (FAZ) and intra-atrial conduction delay zone (CDZ) were measured before and after the drugs. Results: Pilsicainide and flecainide significantly prolonged the ERP-A (211 ± 27 msec to 246 ± 39 msec; p < 0.001, 217 ± 25 msec to 244 ± 33 msec; p < 0.001, respectively) and CT (121 ± 33 msec to 149 ± 43 msec; p < 0.001, 122 ± 22 msec to 153 ± 27 msec; p < 0.001, respectively) to the same degree. However, the Max CD was shortened by pilsicainide, but not by flecainide. The RAFZ, FAZ and CDZ decreased in the P-group (21 ± 25 msec to 4 ± 10 msec; p < 0.01, 24 ± 24 msec to 14 ± 18 msec; p < 0.05, 56 ± 29 msec to 43 ± 32 msec, p < 0.05, respectively), but not in the F-group. Conclusions: The effects of atrial conduction delays may differ between pilsicainide and flecainide. Further examination will be needed to explain this mechanism.


Japanese Circulation Journal-english Edition | 2006

Novel Mutation of Plakophilin-2 Associated With Arrhythmogenic Right Ventricular Cardiomyopathy

Iori Nagaoka; Keiji Matsui; Takeshi Ueyama; Masashi Kanemoto; Jie Wu; Akihiko Shimizu; Masunori Matsuzaki; Minoru Horie


Japanese Circulation Journal-english Edition | 2007

Different effect of the pure Na+ channel-blocker pilsicainide on the ST-segment response in the right precordial leads in patients with normal left ventricular function.

Takeshi Ueyama; Akihiko Shimizu; Toshihiko Yamagata; Masahiro Esato; Masato Ohmura; Yasuhiro Yoshiga; Masashi Kanemoto; Ryousuke Kametani; Akira Sawa; Shinsuke Suzuki; Naoki Sugi; Masunori Matsuzaki


Circulation | 2014

Association of Apixaban Therapy and Prothrombin Time in Patients With Atrial Fibrillation

Masashi Kanemoto; Hiroko Kuhara; Toru Ueda; Takahiro Shinohara; Takamasa Oda; Fumiaki Nakao; Toshiaki Kamei; Yasuhiro Ikeda; Takashi Fujii


Journal of Electrocardiology | 2007

A case of a concealed type of Brugada syndrome with a J wave and mild ST-segment elevation in the inferolateral leads.

Takeshi Ueyama; Akihiko Shimizu; Masahiro Esato; Masashi Kanemoto; Ryousuke Kametani; Akira Sawa; Shinsuke Suzuki; Masunori Matsuzaki


Cardiovascular Intervention and Therapeutics | 2013

Novel and quick coronary image analysis by instant stent-accentuated three-dimensional optical coherence tomography system in catheterization laboratory

Fumiaki Nakao; Tooru Ueda; Shigehiko Nishimura; Hitoshi Uchinoumi; Masashi Kanemoto; Nobuaki Tanaka; Takashi Fujii


Circulation | 2003

Decrease in the spatial dispersion at the termination of atrial fibrillation by intravenous cibenzoline

Hiroyuki Kakugawa; Akihiko Shimizu; Toshihiko Yamagata; Masahiro Esato; Takeshi Ueyama; Yasuhiro Yoshiga; Masashi Kanemoto; Masunori Matsuzaki

Collaboration


Dive into the Masashi Kanemoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge